BiomX Inc.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Gaithersburg, MD.

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX005 in atopic dermatitis were presented at the Revolutionizing Atopic Dermatitis (“RAD”) 2021 Virtual Conference and will also be presented at the upcoming International Conference on Phage Therapy and Bacteriophages. RA

BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX004 in Cystic Fibrosis (“CF”) will be presented at the 44th European Cystic Fibrosis Conference (“ECFS”). ECFS will be held from June 9-12, 2021. “Our upcoming presentation at ECFS highlights the capability of our BOLT p

BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q1 2021 Results - Earnings Call Transcript

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided business updates for the first quarter ended March 31, 2021. “We are off to a strong start in 2021 and are well-positioned to continue making solid progress throughout our entire pipeline of novel phage therapies with the

BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates

Live webinar to be held on Wednesday, May 26th at 8:00 AM EDT Live webinar to be held on Wednesday, May 26th at 8:00 AM EDT

BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Monday, May 24, 2021, at 8:00 a.m. EDT, to report first quarter 2021 financial results and provide business updates. To participate in the conference call, please dial 1-877-407-0

BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021

Using its proprietary BOLT phage therapy platform, BiomX is developing natural and engineered bacteriophage (Phage) therapies to treat chronic diseases and cancer. On March 31st announced 2 phage therapy candidates, BX004 and BX005, for cystic fibrosis (CF) and atopic dermatitis respectively, developed from its BOLT platform now entering Ph. 2 studies.

BiomX: Rapidly Advancing Phage Therapeutics With Multiple Upcoming Catalysts

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will be presenting at two upcoming virtual investor events in April. Presentation Details: Event: Jefferies Microbiome-Based Therapeutics Summit Date: Thursday, April 22, 2021 Time: On-demand beg

BiomX to Present at Upcoming April Investor Events

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q4 2020 Results - Earnings Call Transcript

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020. “2020 was a tremendous year of growth for BiomX, as we expanded our pipeline with programs in cystic fibrosis and atopic dermatitis, both desi

BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live audio webcast on Wednesday, March 31, 2021, at 8:00 a.m. EDT, to report fourth quarter and full year 2020 financial results. To participate in the conference call, please dial 1-877-407-0724 (U.S.), 1-809

BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021

The stock price of BiomX Inc. (NYSEAMERICAN: PHGE) is trading at over 8% pre-market. This is why it happened.

PHGE Stock Price Increases Over 8% Pre-Market: Why It Happened

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the first subject has been dosed in a Phase 2 cosmetic clinical study of BX001 in subjects with mild-to-moderate acne. BX001 is a topical gel comprised of a cocktail of naturally-occurring phage targeting Cutibacterium acnes (C. acnes). C. acnes are bacteria implicated in the pathophy

BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will participate in two upcoming virtual investor conferences. Presentation Details: Event: Chardan's 3rd Annual Microbiome Medicines Summit Date: Monday, March 8, 2021 Time: 10:45 AM EST Event: H.C. Wainwright Global Life Sciences Conference

BiomX to Present at Upcoming March Investor Conferences

BiomX is a clinical-stage microbiome company using its novel BOLT phage therapy platform to develop customized phage therapies to treat chronic diseases ranging from IBC, colorectal cancer, Cystic Fibrosis and acne. 6 programs in its pipeline. Positive Ph 1 data for BX001 in acne. Positive Ph 1a pharmacokinetic data for IBD/PSC evaluating oral delivery. Clinical trial read outs in 2021 and 2022.

BiomX Inc.: Clinical Stage Phage Therapeutics Company Looks Promising

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced positive results of a first-in-human Phase 1a pharmacokinetic study of BX002. BX002 is BiomX's orally administered phage therapy candidate targeting Klebsiella pneumoniae (K. pneumoniae) bacteria in the gut, which have been linked to the pathogenesis of both inflammatory bowel disease (IBD) and

BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences. Event: H.C. Wainwright BioConnect Conference Dates: January 11-14, 2021 Time: Playback available 6 a.m. EST January 11 Webcast link: BiomX - HCW BioConnect Conference Playback The webc

BiomX to Present at Upcoming January Investor Conferences

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced the results of an analysis of presence of target bacteria, Fusobacterium nucleatum, in tumor samples obtained from patients with colorectal cancer and reported on progress in engineering of genetic payloads for therapeutic applications. The analysis confirmed the presence of Fusobacterium nucleat

BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that phages identified by BiomX with a broad host range were able to target and eradicate 89 percent of distinct gut-harbored Klebsiella pneumoniae strains isolated from samples obtained from patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The study includ

BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today reported financial results and a business update for the third quarter ended September 30, 2020. “BiomX continues to lead in the field of phage therapy by implementing proprietary processes for accelerated development,” commented Jonathan Solomon, Chief Executive Officer of BiomX. “Our novel BOLT platform,

BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences. Event: H.C. Wainwright 6th Annual Israel Conference (Virtual) Date: Thursday, Nov. 12, 2020 Time: 9:30 a.m. EST Webcast link: BiomX HCW Israel Conference Live Link and Playback Event:

BiomX to Present at Upcoming November Investor Conferences

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live audio webcast on Thursday, Nov. 12, 2020, at 8:00 a.m. EST, to report third quarter 2020 financial results and provide a corporate update. The conference call dial-in numbers are 1-877-407-0724 (U.S.), 1-809-406-247 (Israel) or 1-201-389-089

BiomX to Report Third Quarter 2020 Financial Results on Nov. 12, 2020

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the first subject has been dosed in a Phase 1a study of BX002, a phage therapy candidate for the treatment of inflammatory bowel disease (IBD). The first-in-human study is designed to evaluate the safety, pharmacokinetics, and ability of orally-administered BX002 to deliver viable phage to

BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Paul Sekhri and Alan Moses, M.D., to its Board of Directors. Mr. Sekhri brings extensive experience in the pharmaceutical and biotech sectors, including senior leadership positions at Teva, Novartis and ARIAD Pharmaceuticals. Dr. Moses brings over 25 years of clinical drug de

BiomX Appoints Paul Sekhri and Alan Moses, M.D., to Board of Directors

BiomX is focused on large market opportunities using the unique approach of manipulating the microbiome utilizing phage therapy.

News for BiomX Inc. Stock (PHGE)